Compare BFST & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BFST | PCRX |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | United States |
| Employees | 842 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 877.1M | 1.0B |
| IPO Year | 2014 | 2010 |
| Metric | BFST | PCRX |
|---|---|---|
| Price | $27.85 | $23.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $32.75 | $30.25 |
| AVG Volume (30 Days) | 142.3K | ★ 512.0K |
| Earning Date | 04-27-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | 23.45 | ★ 107.44 |
| EPS | ★ 0.68 | 0.07 |
| Revenue | $10,704,000.00 | ★ $541,533,000.00 |
| Revenue This Year | $22.71 | $6.78 |
| Revenue Next Year | $5.02 | $8.54 |
| P/E Ratio | ★ $40.96 | $329.14 |
| Revenue Growth | 1.20 | ★ 26.04 |
| 52 Week Low | $22.56 | $18.80 |
| 52 Week High | $30.32 | $27.64 |
| Indicator | BFST | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.28 | 42.19 |
| Support Level | $26.78 | $22.13 |
| Resistance Level | $27.89 | $24.20 |
| Average True Range (ATR) | 0.49 | 1.01 |
| MACD | 0.03 | -0.18 |
| Stochastic Oscillator | 74.42 | 16.85 |
Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates the majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.